SLC26A9 SNP rs7512462 is not associated with lung disease severity or lung function response to ivacaftor in cystic fibrosis patients with G551D-CFTR
- 2 March 2021
- journal article
- research article
- Published by Elsevier BV in Journal of Cystic Fibrosis
- Vol. 20 (5), 851-856
- https://doi.org/10.1016/j.jcf.2021.02.007
Abstract
No abstract availableKeywords
Funding Information
- Cystic Fibrosis Foundation
- NIDDK
This publication has 39 references indexed in Scilit:
- SLC26A9-mediated chloride secretion prevents mucus obstruction in airway inflammationJCI Insight, 2012
- Multiple apical plasma membrane constituents are associated with susceptibility to meconium ileus in individuals with cystic fibrosisNature Genetics, 2012
- A CFTR Potentiator in Patients with Cystic Fibrosis and theG551DMutationThe New England Journal of Medicine, 2011
- The variant call format and VCFtoolsBioinformatics, 2011
- Genome-wide association and linkage identify modifier loci of lung disease severity in cystic fibrosis at 11p13 and 20q13.2Nature Genetics, 2011
- A novel lung disease phenotype adjusted for mortality attrition for cystic fibrosis Genetic modifier studiesPediatric Pulmonology, 2011
- Effect of VX-770 in Persons with Cystic Fibrosis and the G551D-CFTRMutationThe New England Journal of Medicine, 2010
- SLC26A9 stimulates CFTR expression and function in human bronchial cell linesJournal of Cellular Physiology, 2010
- Slc26a9 Is Inhibited by the R-region of the Cystic Fibrosis Transmembrane Conductance Regulator via the STAS DomainOnline Journal of Public Health Informatics, 2009
- Relative Contribution of Genetic and Nongenetic Modifiers to Intestinal Obstruction in Cystic FibrosisGastroenterology, 2006